计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G126387-5mg |
5mg |
现货 ![]() |
| |
| G126387-10mg |
10mg |
现货 ![]() |
| |
| G126387-25mg |
25mg |
现货 ![]() |
| |
| G126387-50mg |
50mg |
现货 ![]() |
| |
| G126387-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | 1032754-93-0 | Apitolisib (USAN/INN) | APITOLISIB [USAN] | GDC-0980,CAS:1032754-93-0 | YOVVNQKCSKSHKT-HNNXBMFYSA-N | J-502360 | GDC-0980 (RG7422) | (S)-1-(4-((2-(2-AMINOPYRIMIDIN-5-YL)-7-METHYL-4-(MORPHOLIN-4-YL)THIENO(3,2-D)PYRIMIDIN-6-YL)METHYL)PIPERAZI |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | GDC-0980 (RG7422) |
| 生化机理 | GDC-0980 (RG7422) 是一种选择性的 PI3 激酶和 mTOR 激酶双重抑制剂,对 PI3Kα、β、δ 和 γ 的 IC50 分别为 5、27、7 和 14 nM。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | PI3 激酶 I 类抑制剂 |
| 产品介绍 |
Apitolisib (GDC-0980, RG7422, GNE 390)是一种有效的,I型PI3K抑制剂,作用于PI3Kα/β/δ/γ,无细胞试验中IC50分别为5 nM/27 nM/7 nM/14 nM,也是mTOR抑制剂,无细胞试验中Ki为17 nM,比作用于其他PIKK家族激酶选择性高。Apitolisib 在胰腺癌细胞中可同时激活自噬与凋亡。 Apitolisib (GDC-0980, RG7422) is a potent, class I PI3K inhibitor for PI3Kα/β/δ/γ with IC50 of 5 nM/27 nM/7 nM/14 nM in cell-free assays, respectively. Also a mTOR inhibitor with Ki of 17 nM in a cell-free assay, and highly selective versus other PIKK family kinases. |
| 纯度 | ≥98% |
| ALogP | 0.2 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504770040 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (2S)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one |
| INCHI | 1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1 |
| InChi Key | YOVVNQKCSKSHKT-HNNXBMFYSA-N |
| Smiles | CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)C(C)O |
| Isomeric SMILES | CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)[C@H](C)O |
| 分子量 | 498.61 |
| Reaxy-Rn | 29348927 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=29348927&ln= |
| 溶解性 | DMSO 20 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
|---|---|
| 密度 | 1.4 |
| 折光率 | 1.68 |
| 沸点 | ~718.6° C at 760 mmHg |
| 熔点 | 222-226°C |
| 分子量 | 498.600 g/mol |
| XLogP3 | 0.200 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 11 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 498.216 Da |
| 单同位素质量Monoisotopic Mass | 498.216 Da |
| 拓扑极表面积Topological Polar Surface Area | 162.000 Ų |
| 重原子数Heavy Atom Count | 35 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 715.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
¥792.72
| 1. Cantley LC. (2002) The phosphoinositide 3-kinase pathway.. Science, 296 (5573): (1655-7). [PMID:12040186] |
| 2. Guertin DA, Sabatini DM. (2007) Defining the role of mTOR in cancer.. Cancer Cell, 12 (1): (9-22). [PMID:17613433] |
| 3. Laplante M, Sabatini DM. (2009) mTOR signaling at a glance.. J Cell Sci, 122 (Pt 20): (3589-94). [PMID:19812304] |
| 4. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. (2010) The emerging mechanisms of isoform-specific PI3K signalling.. Nat Rev Mol Cell Biol, 11 (5): (329-41). [PMID:20379207] |
| 5. Heckerling PS, Leikin JB, Maturen A, Terzian CG, Segarra DP. (1990) Screening hospital admissions from the emergency department for occult carbon monoxide poisoning.. Am J Emerg Med, 8 (4): (301-4). [PMID:2094235] |
| 6. Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, Folks A, Friedman L, Goldsmith R, Gunzner J et al.. (2011) Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.. J Med Chem, 54 (21): (7579-87). [PMID:21981714] |
| 7. Willemsen-Seegers N, Uitdehaag JCM, Prinsen MBW, de Vetter JRF, de Man J, Sawa M, Kawase Y, Buijsman RC, Zaman GJR. (2017) Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.. J Mol Biol, 429 (4): (574-586). [PMID:28043854] |